← Back
NeuroTrials.ai
Neurology Clinical Trial Database

GASS

General Anesthesia versus Sedation, Both with Hemodynamic Control, during Intraarterial Treatment for Stroke: The GASS Randomized Trial

Year of Publication: 2022

Authors: Axelle Maurice, M.D., François Eugène, ..., for the GASS (General Anesthesia versus Sedation for Acute Stroke Treatment) Study Group and the French Society of Anesthesiologists (SFAR) Research Network

Journal: ANESTHESIOLOGY

Citation: ANESTHESIOLOGY 2022; 136:567-76

Link: https://journals.lww.com/anesthesiology/...th_with.12.aspx


Clinical Question

To determine if conscious sedation is associated with a better functional outcome at 3 months compared to general anesthesia in patients undergoing endovascular therapy for acute ischemic stroke due to a large vessel occlusion in the anterior circulation.

Bottom Line

In this trial, standardized general anesthesia and standardized conscious sedation during endovascular treatment for stroke resulted in similar functional outcomes at 3 months. The choice of anesthetic strategy did not significantly impact the primary outcome, suggesting clinicians can use either approach.

Major Points

  • GASS was a multicenter, single-blind, randomized controlled trial that enrolled 345 patients with large vessel occlusion stroke at four centers in France.
  • Patients undergoing endovascular therapy were randomized 1:1 to receive either a standardized conscious sedation protocol or a standardized general anesthesia protocol.
  • A key feature of the trial was that both groups had a standardized protocol for intraoperative blood pressure control.
  • The primary outcome, a favorable functional outcome (modified Rankin Scale [mRS] score of 2 or less) at 3 months, was not significantly different between groups: 36% in the conscious sedation group versus 40% in the general anesthesia group (P=0.474).
  • Patients in the general anesthesia group had a significantly higher rate of successful recanalization (85% vs. 75%; P=0.021) but also experienced longer times from arrival to groin puncture.
  • The incidence of symptomatic intracranial hemorrhage and 3-month mortality was similar in both groups.

Design

Study Type: Investigator-initiated, prospective, multicenter, parallel-group, single-blind, randomized, controlled, superiority trial

Randomization: 1

Blinding: Single-blind (patients, nonmedical research staff, the statistician, and the data and safety monitoring committee were blinded; outcome assessors were blinded).

Enrollment Period: September 2016 to June 2020

Follow-up Duration: 3 months

Centers: 4

Countries: France

Sample Size: 345

Analysis: Intention-to-treat analysis. The primary endpoint was compared between groups using the chi-square test.


Inclusion Criteria

  • Age older than 18 years
  • Admitted to a participating center for occlusion of a large vessel in the anterior cerebral circulation
  • Admitted for endovascular therapy

Exclusion Criteria

  • Already intubated and mechanically ventilated before inclusion
  • Intracerebral hemorrhage associated with the ischemic stroke
  • Contraindicated for conscious sedation (eg, Glasgow Coma Scale less than 8, severe agitation)
  • Contraindicated for succinylcholine (used in the general anesthesia protocol)
  • Inability to walk prior to the current event or history of a previous stroke

Arms

FieldControlConscious Sedation
InterventionStandardized general anesthesia protocol using etomidate, target-controlled infusion of propofol and remifentanil, and succinylcholine, with standardized hemodynamic control (systolic blood pressure 140-185 mmHg).Standardized conscious sedation protocol using target-controlled infusion of remifentanil (maximum target, 2 ng/ml) and local anesthesia, with standardized hemodynamic control (systolic blood pressure 140-185 mmHg).
DurationDuration of the endovascular procedureDuration of the endovascular procedure

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Favorable neurologic outcome, defined as a modified Rankin Scale (mRS) score of 2 or less, assessed at 3 months (range 2 to 6 months) after treatment.Primary40% (66/169)36% (63/176)3.26%0.474
Successful recanalization (modified Thrombolysis in Cerebral Ischemia grade 2b-3)Secondary85% (144/169)75% (131/174)0.021
Time from stroke onset to groin puncture, min (mean±SD)Secondary269±85248±920.040
Mortality at 3 monthsSecondary19% (31/166)16% (28/175)0.514
Symptomatic intracranial hemorrhageAdverse22% (37/169)24% (42/176)0.642
Technical failure of endovascular treatmentAdverse2.3% (4/169)7.3% (13/176)0.044

Subgroup Analysis

Analyses adjusted for baseline NIHSS score and administration of IV thrombolysis did not change the result for the primary outcome.


Criticisms

  • The primary outcome was assessed in a wider time-frame (2 to 6 months) than the planned 3 months for logistical reasons.
  • A systematic post-procedural scan at day 1 to assess infarct volume (eg, ASPECTS) was not performed as it was not standard practice at the time of study design.
  • The study population had a lower rate of good functional outcome and a higher mortality rate compared to some other stroke trials, which may be related to the older age of the cohort.

Funding

French Ministry of Health

Based on: GASS (ANESTHESIOLOGY, 2022)

Authors: Axelle Maurice, M.D., François Eugène, ..., for the GASS (General Anesthesia versus Sedation for Acute Stroke Treatment) Study Group and the French Society of Anesthesiologists (SFAR) Research Network

Citation: ANESTHESIOLOGY 2022; 136:567-76

Content summarized and formatted by NeuroTrials.ai.